Pricing Log in Create free account

Precigen, Inc. (PGEN) vs SELLAS Life Sciences Group, Inc. (SLS)

Precigen, Inc. and SELLAS Life Sciences Group, Inc. are both Biotechnology companies. Precigen, Inc. and SELLAS Life Sciences Group, Inc. are of similar size ($1.7B and $1.7B). SELLAS Life Sciences Group, Inc. has negative trailing earnings, so its P/E is not meaningful; Precigen, Inc. trades at 63.8×. Precigen, Inc. has the higher net margin (15.6% vs 0.00%) and the higher return on invested capital (15.9% vs 0.00%). Across the 16 metrics below, Precigen, Inc. leads on 10 and SELLAS Life Sciences Group, Inc. on 6.

Valuation

Metric PGEN SLS Biotechnology median
P/E 63.81 n/m 11.58
P/S 10.71 151.89 9.61
P/B 20.05 11.59 2.26
Price to free cash flow n/m n/m 26.41
EV/EBITDA 45.87 n/m 0.72
EV/Sales 11.10 138.74 9.43
Earnings yield 1.57% (2.49%) (32.28%)
Free cash flow yield (4.42%) (2.41%) (22.27%)

Profitability

Metric PGEN SLS Biotechnology median
Gross margin 91.42% 0.00% 68.81%
Operating margin 21.43% 0.00% 0.00%
Net margin 15.55% 0.00% 0.00%
Free cash flow margin (47.35%) 0.00% 0.00%
Return on equity 38.84% (39.63%) (50.30%)
Return on assets 12.73% (36.54%) (45.47%)
Return on invested capital 15.93% 0.00% 0.00%

Growth

Metric PGEN SLS Biotechnology median
Revenue growth (TTM) 2,387.61% — 6.78%
EPS growth (last fiscal year) (191.49%) 50.00% 29.88%
Revenue growth, 5-year CAGR (21.26%) — 9.75%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric PGEN SLS Biotechnology median
Debt to equity 1.12 0.00 0.00
Current ratio 5.58 18.83 4.74
Net debt to EBITDA 0.04 2.54 1.01

Dividend

Metric PGEN SLS Biotechnology median
Dividend yield — — 0.39%
Payout ratio — — —

Size

Metric PGEN SLS Biotechnology median
Market cap 1.69b 1.70b 168.63m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack